Literature DB >> 23246909

An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy.

Mark J Millan1.   

Abstract

Neurodevelopmental disorders (NDDs) are characterized by aberrant and delayed early-life development of the brain, leading to deficits in language, cognition, motor behaviour and other functional domains, often accompanied by somatic symptoms. Environmental factors like perinatal infection, malnutrition and trauma can increase the risk of the heterogeneous, multifactorial and polygenic disorders, autism and schizophrenia. Conversely, discrete genetic anomalies are involved in Down, Rett and Fragile X syndromes, tuberous sclerosis and neurofibromatosis, the less familiar Phelan-McDermid, Sotos, Kleefstra, Coffin-Lowry and "ATRX" syndromes, and the disorders of imprinting, Angelman and Prader-Willi syndromes. NDDs have been termed "synaptopathies" in reference to structural and functional disturbance of synaptic plasticity, several involve abnormal Ras-Kinase signalling ("rasopathies"), and many are characterized by disrupted cerebral connectivity and an imbalance between excitatory and inhibitory transmission. However, at a different level of integration, NDDs are accompanied by aberrant "epigenetic" regulation of processes critical for normal and orderly development of the brain. Epigenetics refers to potentially-heritable (by mitosis and/or meiosis) mechanisms controlling gene expression without changes in DNA sequence. In certain NDDs, prototypical epigenetic processes of DNA methylation and covalent histone marking are impacted. Conversely, others involve anomalies in chromatin-modelling, mRNA splicing/editing, mRNA translation, ribosome biogenesis and/or the regulatory actions of small nucleolar RNAs and micro-RNAs. Since epigenetic mechanisms are modifiable, this raises the hope of novel therapy, though questions remain concerning efficacy and safety. The above issues are critically surveyed in this review, which advocates a broad-based epigenetic framework for understanding and ultimately treating a diverse assemblage of NDDs ("epigenopathies") lying at the interface of genetic, developmental and environmental processes. This article is part of the Special Issue entitled 'Neurodevelopmental Disorders'.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23246909     DOI: 10.1016/j.neuropharm.2012.11.015

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  66 in total

1.  Epigenetic analysis of neurocognitive development at 1 year of age in a community-based pregnancy cohort.

Authors:  Julia Krushkal; Laura E Murphy; Frederick B Palmer; J Carolyn Graff; Thomas R Sutter; Khyobeni Mozhui; Collin A Hovinga; Fridtjof Thomas; Vicki Park; Frances A Tylavsky; Ronald M Adkins
Journal:  Behav Genet       Date:  2014-01-23       Impact factor: 2.805

Review 2.  Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.

Authors:  Barry Boland; Wai Haung Yu; Olga Corti; Bertrand Mollereau; Alexandre Henriques; Erwan Bezard; Greg M Pastores; David C Rubinsztein; Ralph A Nixon; Michael R Duchen; Giovanna R Mallucci; Guido Kroemer; Beth Levine; Eeva-Liisa Eskelinen; Fanny Mochel; Michael Spedding; Caroline Louis; Olivier R Martin; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

Review 3.  Comorbidities in Neurology: Is adenosine the common link?

Authors:  Detlev Boison; Eleonora Aronica
Journal:  Neuropharmacology       Date:  2015-05-13       Impact factor: 5.250

4.  No increase in autism-associated genetic events in children conceived by assisted reproduction.

Authors:  Sean Ackerman; Julia Wenegrat; David Rettew; Robert Althoff; Raphael Bernier
Journal:  Fertil Steril       Date:  2014-05-17       Impact factor: 7.329

Review 5.  Epigenetic regulation of pluripotency and differentiation.

Authors:  Michael J Boland; Kristopher L Nazor; Jeanne F Loring
Journal:  Circ Res       Date:  2014-07-07       Impact factor: 17.367

Review 6.  Altering the course of schizophrenia: progress and perspectives.

Authors:  Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2016-03-04       Impact factor: 84.694

Review 7.  Neurobiology of autism gene products: towards pathogenesis and drug targets.

Authors:  Kristel T E Kleijer; Michael J Schmeisser; Dilja D Krueger; Tobias M Boeckers; Peter Scheiffele; Thomas Bourgeron; Nils Brose; J Peter H Burbach
Journal:  Psychopharmacology (Berl)       Date:  2014-01-14       Impact factor: 4.530

8.  Placental HTR2A methylation is associated with infant neurobehavioral outcomes.

Authors:  Alison G Paquette; Corina Lesseur; David A Armstrong; Devin C Koestler; Allison A Appleton; Barry M Lester; Carmen J Marsit
Journal:  Epigenetics       Date:  2013-06-19       Impact factor: 4.528

9.  Chronic Ethanol Exposure Alters DNA Methylation in Neural Stem Cells: Role of Mouse Strain and Sex.

Authors:  Shayan Amiri; James R Davie; Mojgan Rastegar
Journal:  Mol Neurobiol       Date:  2019-08-14       Impact factor: 5.590

10.  Parent ratings of ability to consent for clinical trials in fragile X syndrome.

Authors:  Donald B Bailey; Melissa Raspa; Anne Wheeler; Anne Edwards; Ellen Bishop; Carla Bann; David Borasky; Paul S Appelbaum
Journal:  J Empir Res Hum Res Ethics       Date:  2014-07       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.